AbbVie’s pending Allergan takeover moves closer after drug divestments
Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase), in a development meant to satisfy antitrust regulations in the US.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 September 2021 Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima.
15 June 2021 Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.
20 July 2020 AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.
